India's Bharat Biotech has recently completed the Phase III trials of its COVID-19 intranasal vaccine BBV154 and submitted the data to the Drug Controller General of India (DCGI) for approval both as a primary two-dose vaccine, and a heterologous booster dose. However, the company has not yet made clinical trial results publicly available.
BBV154 could be the second approved intranasal vaccine for COVID-19 in the world. Based on the novel adenovirus vector, BBV154 is an intranasal vaccine for COVID-19 which stimulates a broad immune response neutralizing IgG, mucosal IgA, and T cell responses, he said. Most importantly, it is effective for blocking both infection and transmission of the novel coronavirus.
In April 2022, the Russian Health Ministry approved Sputnik V nasal vaccine, before which it was only available as an intramuscular injection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze